文献类型： 外文期刊

作者： Zhao, Zhongxin ¹ ; Zheng, Wenwen ¹ ; Yan, Lina ¹ ; Sun, Peilu ² ; Xu, Tong ¹ ; Zhu, Yelei ³ ; Liu, Lele ¹ ; Tian, Li ¹ ; He, ¹ ;

作者机构： 1.Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Virol, Jinan, Peoples R China

2.Shandong Acad Med Sci, Inst Mat Med, Key Lab Rare & Uncommon Dis Shandong Prov, Key Lab Biotech Drugs,Minist Hlth, Jinan, Peoples R China

3.Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou, Peoples R China

4.Shandong Normal Univ, Coll Life Sci, Dept Biol Sci, Jinan, Peoples R China

5.Xinjiang Acad Anim Sci, Inst Vet Med, Urumqi, Peoples R China

关键词： severe fever with thrombocytopenia syndrome virus; rabies virus; adenovirus type 5; bivalent vaccine; virus-neutralizing antibody

期刊名称：FRONTIERS IN MICROBIOLOGY （ 影响因子：5.64； 五年影响因子：6.32 ）

ISSN： 1664-302X

年卷期： 2020 年 11 卷

页码：

收录情况： SCI

摘要： Both severe fever with thrombocytopenia syndrome (SFTS) and rabies are severe zoonotic diseases. As co-hosts of rabies virus (RABV) and SFTS virus (SFTSV), dogs and cats could not only be infected but also transmit the virus to human. Hence, developing a bivalent vaccine against both SFTS and rabies is urgently needed. In this study, we generated a recombinant replication-deficient human adenovirus type 5 (Ad5) co-expressing RABV G and SFTSV Gn (Ad5-G-Gn) and evaluated its immunogenicity and efficacy in mice. Ad5-G-Gn immunization activated more dendritic cells (DCs) and B cells in lymph nodes (LNs) and induced Th1-/Th2-mediated responses in splenocytes, leading to robust production of neutralizing antibodies against SFTSV and RABV. In addition, single dose of Ad5-G-Gn conferred mice complete protection against lethal RABV challenge and significantly reduced splenic SFTS viral load. Therefore, our data support further development of Ad5-G-Gn as a potential bivalent vaccine candidate against SFTS and rabies for dog and cat use.